HTFL 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-13

• The percentage of our U.S. revenue cases attributable to office and clinic-based accounts was 36% and 31% for the three months ended June 30, 2026 and 2025, respectively, and 36% and 31% for the six months ended June 30, 2026 and 2025, respectively.

• While a single customer may include multiple accounts, no single customer accounted for 10% or more of our revenue during the three and six months ended June 30, 2026 and 2025. However, the decision-making function for some of these accounts is concentrated in a relatively small number of customers,…

• Research and development expenses are incurred in connection with the advancement of the Heartflow Platform with the goal to introduce products, features and improvements aimed at increasing the value proposition for our customers by expanding its applicability to additional disease states and patie…

• costs incurred by our production team to support clinical trials and research and development efforts, and allocated overhead, including facilities expenses, equipment and depreciation. Our research and development team is comprised of PhD research scientists with expertise in AI-based algorithms an…

• Interest income (expense), net increased to income of $2.3 million during the three months ended June 30, 2026, compared to an expense of $6.0 million during the three months ended June 30, 2025. This change was mainly attributable to the repayment in full of our 2024 Term Loan in August 2025 and th…

相对上期删除的文字 · 来源:10-Q · 2026-05-14

• While a single customer may include multiple accounts, no single customer accounted for 10% or more of our revenue during the three months ended March 31, 2026 and 2025. However, the decision-making function for some of these accounts is concentrated in a relatively small number of customers, such t…

• result in a disproportionate loss across our accounts. As we expand the adoption of the Heartflow Platform, we expect a majority of new accounts to come from new customers, decreasing our customer concentration risk.

• Research and development expenses are incurred in connection with the advancement of the Heartflow Platform with the goal to introduce products, features and improvements aimed at increasing the value proposition for our customers by expanding its applicability to additional disease states and patie…

• populations for our products and to hire additional personnel to develop new product offerings and product enhancements. For example, in the second half of 2026, we expect to begin enrollment in three randomized clinical trials focused on high-risk asymptomatic sub populations to expand the addressa…

• Asset impairment charge consists of a non-cash impairment charge related to the right-of-use asset and leasehold improvements for our Mountain View, California facility. In March 2026, we entered into a sublease agreement with a third-party subtenant to sublease this facility. We evaluated the assoc…

相对上期新增的文字 · 来源:10-Q · 2026-08-13

• The vast majority of our cash generated from revenue is denominated in U.S. dollars, with a small amount denominated in other foreign currencies. Our expenses are generally denominated in the currencies of the jurisdictions in which we conduct our operations, which are primarily in the United States…

相对上期删除的文字 · 来源:10-Q · 2026-05-14

• The vast majority of our cash generated from revenue is denominated in U.S. dollars, with a small amount denominated in other foreign currencies. Our expenses are generally denominated in the currencies of the jurisdictions in which we conduct our operations, which are primarily in the United States…

• Kingdom and Japan. Our results of operations and cash flows are, therefore, subject to fluctuations due to changes in foreign currency exchange rates. The effect of a hypothetical 10% change in foreign currency exchange rates applicable to our business would not have had a material impact on our con…

相对上期新增的文字 · 来源:10-Q · 2026-08-13

• On June 4, 2026, Vikram Verghese, our Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 106,982 shares of our common stock. The duration of the trading arrangement is until December 31, 2026, or earlier if all transac…

• On June 16, 2026, Campbell D.K. Rogers, M.D., our Chief Medical Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 91,746 shares of our common stock. The duration of the trading arrangement is until December 18, 2026, or earlier if al…

• In addition, in Item 9B of Part II of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, we inadvertently omitted the disclosure of a new Rule 10b5-1 trading arrangement entered into by Campbell D.K. Rogers, M.D. on December 12, 2025, which provided for the sale from time to…